Showing 1 posts of 1 posts found.
The FDA has given the go-ahead for Amgen’s hyperparathyroidism (HPT) therapy Parsabiv (etelcalcetide), marking the first new treatment for patients …
Weber is new CMO at Sensorion
Charity commits £800,000 to AI research into late breast cancer recurrence
AstraZeneca’s Trixeo approved in EU for asthma in patients aged 12 and over
Acumetis CEO Herspiegel steps down as Burden assumes role
Sobi’s olezarsen recommended for EU approval in severe hypertriglyceridaemia